Nkarta Inc

NKTX exhibits a clear sequence of higher highs and higher lows within a Stage 2 advance, with price accepting pullbacks into rising EMAs and reclaiming support. The medium-term structure remains bullish, reinforced by our Speculative strategy’s preference for continuation setups. Short-term timing is favorable as price tracks above the 9/20 EMAs and rebounds from recent consolidation. We recommend engaging now on a pullback interaction around the EMA zone, targeting continuation of the established uptrend.

• ↑Cash burn down 16% to ~$88M/year; $230M reserves support 2.6-year runway
• ↑FDA-approved Ntrust-1/2 protocol changes reduce patient burden and speed trials
• ↓Q1’26 net loss of $0.37/shr vs. est. $0.38; no revenue generation